Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen
NN9541-7841
Phase 2 small_molecule active
Quick answer
Placebo A, NNC0519-0130, Ozempic 0.5 mg solution for injection in pre-filled pen for Chronic Kidney Disease, with or without Type 2 diabetes, Obesity is a Phase 2 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Chronic Kidney Disease, with or without Type 2 diabetes, Obesity
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active